Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: Post hoc analysis of the Irbesartan Diabetic Nephropathy Trial

Nephrology Dialysis Transplantation

Volumn 27, Issue 6, 2012, Pages 2255-2263

  Evans, Marc ^a   Bain, Stephen C ^b   Hogan, Simon ^c   Bilous, Rudy W ^d,e  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b SWANSEA UNIVERSITY   (United Kingdom)

^c Sanofi aventis Ltd   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Chronic kidney disease; Diabetes; Diabetic nephropathy; Glomerular filtration rate; Irbesartan

Indexed keywords

AMLODIPINE; INSULIN; IRBESARTAN; PLACEBO; POTASSIUM;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CREATININE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROTEINURIA; TETRAZOLES;

EID: 84861889128     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr696     Document Type: Article

References (38)

1. International Diabetes Federation. IDF Diabetes Atlas 2009. http://www.diabetesatlas.org/content/diabetes-and-impaired-glucose-tolerance (18 June 2010, date last accessed)
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14
3. Stel VS, Kramer A, Zoccali C et al. The 2007 ERA-EDTA Registry Annual Report-a Precis. NDT Plus 2009; 2: 514-521
4. United States Renal Data System (USRDS). Annual Data Report 2010. http://www.usrds.org/adr.htm (6 April 2011, date last accessed)
5. Kramer A, Stel V, Zoccali C et al. An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006. Nephrol Dial Transplant 2009; 24: 3557-3566
6. Burrows NR, Li Y, Geiss LS. Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline. Diabetes Care 2010; 33: 73-77
7. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-266
8. National Collaborating Centre for Chronic Conditions. Chronic Kidney Disease: National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care. London, UK: Royal College of Physicians, 2008
9. Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol 2010; 6: 319-330
10. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitorassociated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160: 685-693
11. Tonelli M, Gill J, Pandeya S et al. Barriers to blood pressure control and angiotensin enzyme inhibitor use in Canadian patients with chronic renal insufficiency. Nephrol Dial Transplant 2002; 17: 1426-1433
12. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
13. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
14. Levey AS, Coresh J, Balk E et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147
15. Taal M, Tomson C.UKRenal Association Clinical Practice Guidelines Module 1: Chronic Kidney Disease 2007. http://www.renal.org/pages/media/download- gallery/CKDglinesreformatjan08.pdf (6 April 2011, date last accessed)
16. Hunsicker LG, Atkins RC, Lewis JB et al. Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. Kidney Int Suppl 2004; 92: S99-S101
17. Rodby RA, Rohde RD, Clarke WR et al. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. Nephrol Dial Transplant 2000; 15: 487-497
18. Kraemer HC, Wilson GT, Fairburn CG et al. Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry 2002; 59: 877-883
19. Pinheiro J, Bates D. Mixed-Effects Models in S and S-PLUS (Statistics and Computing). New York, NY: Springer Verlag; 2000
20. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612
21. Rossing K, Christensen PK, Hovind P et al. Progression of nephropathy in type 2 diabetic patients. Kidney Int 2004; 66: 1596-1605
22. Abbate M, Zoja C, Corna D et al. In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol 1998; 9: 1213-1224
23. Nangaku M, Ohse T, Tanaka T et al. Renoprotection with antihypertensives: reduction of proteinuria and improvement of oxygenation via inhibition of the renin-angiotensin system. Curr Hypertens Rev 2005; 1: 67-76
24. Zatz R, Dunn BR, Meyer TW et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925-1930
25. He J, Whelton PK. Elevated systolic blood pressure as a risk factor for cardiovascular and renal disease. J Hypertens Suppl 1999; 17: S7-13
26. Pohl MA, Blumenthal S, Cordonnier DJ et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 2005; 16: 3027-3037
27. Ceriello A, Assaloni R, Da Ros R et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 2005; 111: 2518-2524
28. Ceriello A, Assaloni R, Da Ros R et al. Effect of irbesartan on nitrotyrosine generation in non-hypertensive diabetic patients. Diabetologia 2004; 47: 1535-1540
29. Koh KK, Han SH, Chung WJ et al. Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. Am J Cardiol 2004; 93: 1432-1435 A10
30. Koylan N, Oflaz H, Meric M. The effects of irbesartan versus atenolol on endothelial dysfunction in patients with type II diabetes and hypertenion. J Clin Hypertens 2007; 9: 49 Abstract P107
31. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
32. Persson F, Rossing P, Hovind P et al. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. Diabetes 2006; 55: 3550-3555
33. Sola S, Mir MQ, Cheema FA et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 2005; 111: 343-348
34. Kagami S, Border WA, Miller DE et al. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431-2437
35. Wolf G, Haberstroh U, Neilson EG. Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 1992; 140: 95-107
36. Benson SC, Pershadsingh HA, Ho CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002
37. Chen S, Ge Y, Si J et al. Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade. Kidney Int 2008; 74: 1128-1138
38. Holtkamp FA, de Zeeuw D, Thomas MC et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 2011; 80: 282-287